Institutional members access full text with Ovid®

Share this article on:

Phase 1 Safety Assessment of Intrathecal Oxytocin

Eisenach, J.C.; Tong, C.; Curry, R.

Obstetric Anesthesia Digest: March 2016 - Volume 36 - Issue 1 - p 55
doi: 10.1097/01.aoa.0000479537.59060.1a
Short Takes

(Anesthesiology. 2015;122:407–413)

Existing evidence has suggested that oxytocin has potential as an analgesic, but when administered systemically, it only enters the central nervous system at small levels and does not reduce nociception in humans. Systemic oxytocin is also known to cause hypotension, QT interval prolongation, and hyponatremia, and other side effects.

Department of Anesthesiology, Wake Forest School of Medicine, Winston-Salem, NC

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved